Manuel Carrondo | Prof
iBET: Instituto de Biologia Experimental e Tecnológica

Manuel Carrondo, Prof, iBET: Instituto de Biologia Experimental e Tecnológica

Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and PhD in (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation in, Biochemical Engineering (1991), NOVA-Univ. Nova de Lisboa. Full Professor, Chemical and Biochemical Engineering, Faculty of Sciences and Technology, NOVA- Univ. Nova de Lisboa (1995-present). Founder (1988), earlier president and CEO (currently vice –president) of iBET – Institute for Experimental and Technological Biology (www.ibet.pt), founder and board member of the Portuguese Academy of Engineering (1998-2001) and board member of the Euro CASE (Council on Applied Science and Engineering) (1998-2001), chairman of the ESACT - European Society of Animal Cell Technology (ESACT) (1997-2001) and of Medical Biotechnology Section of the European Federation of Biotechnology (EFB) (1999-2001), member and Vice- Chairman of the External Advisory Group “Cell Factory” (Research Directorate General, European Commission) (1998-2002), Portuguese High Level Representative at EUREKA Programme (1993-1996), member of the Advisory Board of Max-Planck Institute for Dynamics of Complex Technical Systems, Magdeburg (2008-2014), KGI-Keck Graduate Institute, Claremont, California (2007-...), CEVEC Pharmaceuticals, Köln (2007-...), PBS Biotech, California (2009-…), CNIC - Spanish National Center for Cardiovascular Research Carlos III, Spain (2011-2014), Masthercells - Manufacturing Synergies for Therapeutic Cells, Belgium (2012-2014) and Alloksys - Life Sciences BV, Holland (2012-…), OECD - Portuguese representative to the Working Party on Biotechnology, Nanotechnology and Converging Technologies - (2014-...), iNOVA4Health - Advancing Precision Medicine, Portugal, Unit Coordinator – (2015-…); IBMT - Fraunhofer Institute for Biomedical Engineering, St. Ingbert, Germany, Advisory Board Member - (2016-…). Meeting Chairman of the ESACT 14th Meeting “Animal Cell Technology: From Vaccines to Genetic Medicine”, Vilamoura, May 1996 and of the “3rd Recombinant Protein Production Meeting: A comparative view on host physiology", Tavira-Algarve (Portugal), November 2004. Visiting Professor at Carnegie-Mellon Univ. (1981), Massachusetts Institute of Technology - MIT (1984, 1988), Gesellschaft für Biotechnologische Forschung (1989 and 1993), Visiting Professor, COPPE, Univ. Federal do Rio de Janeiro, Brazil (January 2014 - …). Supervised 32 PhD students (thesis defended) and published over two hundred and thirty papers in refereed international journals; Associate-Editor of Journal of Biotechnology (2000-2016), member of the editorial board of Biotechnology and Bioengineering, Current Gene Therapy and Biotechnology Letters; referee of Biotechnology Progress, Cytotechnology, Applied Microbiology and Biotechnology, Enzyme and Microbial Biotechnology. Key areas of research interest: Animal Cell Technology and its application for human and animal health (http://tca.itqb.unl.pt). Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-, baculo-) as deliverables for gene therapy; cell therapies and stem cells. cGMP pilot plant scale-

Appearances:



Conference Day 1: Thursday 16th May 2019 @ 14:10

Chair's opening remarks

Conference Day 1: Thursday 16th May 2019 @ 16:45

Continuous, integrated processes supporting robust and cost-effective viral vector productions

  • Real data from constitutive production and from continuous downstream purification of, eg., lentivirus and oncolytic viruses confirms these as key steps to improve consistency, robustness and reduced costs of goods for cell and gene therapy.

Conference Day 1: Thursday 16th May 2019 @ 17:00

PANEL: progress and challenges in Viral Vector Manufacturing: assays and analysis

How to look at the percentage empty vs filled viral particles  Looking a potency of construct, how can this be measured and what are the tools? Infection of cell: analysing gene expression, functionality, level and potency 
last published: 17/Jan/19 16:45 GMT

back to speakers

 

TO SPONSOR / EXHIBIT

Erica Baeta
+44 (0)207 092 1152
erica.baeta@terrapinn.com

TO SPEAK

Jessica Robinson
t/ +44 (0)207 092 1150
jessica.robinson@terrapinn.com

TO REGISTER

Issa Mauthoor
+44 (0)207 092 1257
issa.mauthoor@terrapinn.com